Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial

Video

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Following results that were reported at the 2020 San Antonio Breast Cancer Symposium, investigators of the phase 3 RxPONDER trial (NCT01272037) hope to further evaluate the clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and an Oncotype DX Recurrence Score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of both the Glenn Family Breast Center and of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about next steps following the phase 3 RxPONDER trial.

Transcription:

I have a lot of work to do. We were only reporting at about 50% of the events, so we’re still awaiting additional events. And we’ll put this out as data come. We’ll also be reporting things like quality-of-life outcomes and other end points. And then there’s also a translational medicine component to this where we’ve collected primary tissue and lymph nodes involved that weren’t involved, in the hopes that we could also look at additional predictors or prognostic signatures that can help inform this patient population and potentially future studies as well.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content